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Flora M. Hammond1*, David N. Alexander2, Andrew J. Cutler3, Stephen D’Amico4, Rachelle S. Doody5,
William Sauve6, Richard D. Zorowitz7, Charles S. Davis8, Paul Shin9, Fred Ledon9, Charles Yonan9,
Andrea E. Formella9 and Joao Siffert9Erratum
After publication of the original article [1], the authors
noticed that there were errors in the caption of Fig. 3,
and the y-axis of Fig. 6 itself.
The following statement should not have been in-
cluded in the caption of Fig. 3: “CNS-LS scores were not
normalized.” The CNS-LS is a rank-order scale, and is
not normalized. This statement was included errone-
ously and the authors intended on removing it prior to
resubmission, but this was unfortunately overlooked.
Similarly, the y-axis within Fig. 6 was mislabelled. The
CNS-LS scale ranges from 7 to 35, so the y-axis for Fig.
6 should start at a base score of 7 and not zero. The cor-
rect and updated version of Fig. 6, in which the data pre-
sented remain accurate and are unchanged, is published
in this erratum.
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Fig. 6 Mean CNS-LS Scores Across DM/Q Studies for PBA Secondary to Diverse Neurologic Conditions. *DM/Q 30/30 mg twice daily;
†DM/Q 20/10 mg twice daily. ‡Improvement from baseline in mean CNS-LS (SE). 99-AVR-102 (4 week study comparing DM/Q to DM or Q
monotherapy): End of study is the mean of the CNS-LS scores for Days 15 and 29; P = 0.001 vs. dextromethorphan comparator and P <
0.001 vs quinidine comparator. 02-AVR-106 (12 week DBPC study): End of study is the mean of the CNS-LS scores on Days 15, 29, 57,
and 85; P < 0.0001 vs. placebo. 07-AVR-123 (12 week DBPC study): End of study is at Week 12 intent to treat; P < 0.05 vs. placebo. PRISM
II: End of study is at Day 90/Final Visit; P < 0.001 vs. baseline in all 3 cohorts. ALS = amyotrophic lateral sclerosis; CNS-LS = Center for
Neurologic Study–Lability Scale; DM/Q = dextromethorphan/quinidine; MS = multiple sclerosis; PBA = pseudobulbar affect; TBI = traumatic
brain injury; SE = standard error
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